Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-11-07
2006-11-07
Chernyshev, Olga N. (Department: 1649)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S184100, C424S185100, C424S116000, C514S019300, C514S002600
Reexamination Certificate
active
07132104
ABSTRACT:
The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1–36). As a consequence of the resulting enhanced stability of the endogenous NPY (1–36) caused by the inhibition of DP IV activity, NPY activity is prolonged thereby resulting among other things in functionally active NPY Y1 receptor activity thereby facilitating anti-depressive, anxiolytic, analgesic, anti-hypertension and other neurological effects.
REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4024250 (1977-05-01), Palm
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6319893 (2001-11-01), Demuth et al.
patent: 25 42598 (1976-04-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-09-01), None
patent: 0 995 440 (2000-04-01), None
patent: 2085665 (1971-03-01), None
patent: 2696740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO00/01849 (2000-01-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 01/62266 (2001-08-01), None
Lader, 1981, J.Clinical Psycopharmacology, vol. 1, No. 6, pp. 342-349.
Tobin and Dusheck, , 1998, Asking about life, Sunders Coolege Publishing, p. 799.
Campbell, I.W. New Antidiabetic Drugs, ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and metformin: efficacy and inadequacy”. 3:33-51 (1990).
Mercla Index, 11thEdition, p. 934, 1979.
Martindale The Extra Pharmacopeia, 30thEdition, Pharmaceutical Press, 1993, p. 1619.
Chemical Abstracts, vol. 115. No. 15, Oct. 14, 1991 Columbus, Ohio, US; abstract No. 149947q, Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts, vol. 126, No. 2, Jan. 13, 1997 Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Chemical Abstracts, vol. 118, No. 25, Jun. 21, 1993 Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors”, Nov. 20, 1992.
Arai et al: “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain” Chemical and Pharmaceutical Bulletin., Bd. 41, Nr. 9, 1993.
J. Lin et al.: “Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics” Proceedings of the National Academy of Sciences of USA, vol. 95, Nov. 1998, pp. 14020-14024.
Korom, S., et al “Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients”, Transplantation vol. 63, 1495-1500 No. 10 (1997).
Tanka, S., et al., “Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV”. Int. J. Immunopharmacol, vol. 19, No. 1 pp. 15-24, 1997.
Mentlein, R., et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”. Regul. Pept. 49, 133-144(1993).
Wetzl, W., et al., “Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes”. Neuropeptides, 31, 41-45 (1997).
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed inXenopus laevisoocytes”. J. Physiol. 504, 169-174 (1997).
Durinx, C.; et al.; “Reference Values for Plasma Dipepidyl-Pepidase IV activity and their Association with Other Laboratory Parameters”. Clin Chem Lab Med 2001, Feb.; 39 (2) :155-9, 1 page.
Gossrau, R.; “Cytochemistry of Membrane Proteases”. Histochem J, Jul. 1985; 17 (7) :737-71, 1 page.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae”. Acta Histochem 1993, Dec., 1995 (2) :185-92, 1 page.
Heymann, E.; et al.; “Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.” Klin Wochenschr, Jan., 1984, 2;62 (1) :2-10, 1 page.
Magyar, C.E.; et al.; “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.” Am J Physiol Renal Physiol, Aug. 2000; 279 (2) :F358-69, 1 page.
Papies, B.; et al.; “Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension.” Cor Vasa, 1991; 33 (3) :218-26, 1 page.
Qureshi. N.U.; et al., “Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock”. Regul Pept, Sep. 25, 1998; 75-76:215-20, 1 page.
Index Nominum, International Drug Directory 1992/1993, Medpharm Scientific Publishers, pp. 728-729.
The Merck Index, 9thEdition, 1976, p. 773.
C.J. Bailey et al.,New Antidiabetic Drugs, Smith-Gordon Nishimura, 1990, p. 36.
The Merck Index, 12thEdition, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, p. 1014.
Martindale The Extra Pharmacopoeia, 30thEdition, London Pharmaceutical Press, 1993, p. 36.
Heymann, E.; et al.; “Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.”Klin Wochenschr, Jan., 1984, 2;62 (1) :2-10, 1 page.
The Merck Index, An Encyclopedia of Chemicals and Drugs, 9thEdition, Merck & Co., Inc., 1976, p. 773.
C.B. Welch,Medical Management of Non-Insulin-Dependent(Type II)Diabetes, 3rdedition, American Diabetes Association, “Diagnosis and Classification” p. 3, 1994, Pharmacologic Intervention (2 pages).
Mannucci et al.,Diabetes Care, “Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects”, 24(3): 489-494, Mar. 2001.
Stryer,Biochemistry 3rdEd., “Protein Conformation, Dynamics, and Function”, 1988, p. 191-193.
Pauly et al.,Regulatory Peptides, “Abstracts Issue: Abstracts from the 11thInternational Symposium on Regulatory Peptides”, Jul. 15, 1996, 64(1-3): 148 plus cover.
Gutniak et al.,New England Journal of Medicine, “Antidiabetogenic Effect of Glucagon-like peptide-1 (7-36) Amide in Normal Subjects and Patients Wi
Demuth Hans-Ulrich
Hoffmann Matthias
Kask Ants
Kruber Susanne
Nguyen Huu Phuc
Chernyshev Olga N.
Probiodrug (AG)
Sonnenschein Nath & Rosenthal LLP
LandOfFree
Modulation of central nervous system (CNS) dipeptidyl... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of central nervous system (CNS) dipeptidyl..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of central nervous system (CNS) dipeptidyl... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3679868